Virtual screening based on molecular docking of lysosomotropic compounds as therapeutic agents for COVID-19
DOI:
https://doi.org/10.12662/2317-3076jhbs.v10i1.4238.p1-12.2022Palavras-chave:
Lysosomotropic agents, SARS-CoV, Molecular DockingResumo
Objective: Analyze lysosomotropic agents and their action on COVID-19 targets using the molecular docking technique. Methods: Molecular docking analyses of these lysosomotropic agents were performed, namely of fluoxetine, imipramine, chloroquine, verapamil, tamoxifen, amitriptyline, and chlorpromazine against important targets for the pathogenesis of SARS-CoV-2. Results: The results revealed that the inhibitors bind to distinct regions of Mpro COVID-19, with variations in RMSD values from 1.325 to 1.962 Å and binding free energy of -5.2 to -4.3 kcal/mol. Furthermore, the analysis of the second target showed that all inhibitors bonded at the same site as the enzyme, and the interaction resulted in an RMSD variation of 0.735 to 1.562 Å and binding free energy ranging from -6.0 to -8.7 kcal/mol. Conclusion: Therefore, this study allows proposing the use of these lysosomotropic compounds. However, these computer simulations are just an initial step toward conceiving new projects for the development of antiviral molecules.
Downloads
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Os artigos publicados na JHBS são de uso gratuito, destinados a aplicações educacionais e não comerciais.
Este artigo está licenciada sob uma licença Creative Commons - Atribuição-Não Comercial- Sem Derivações 4.0 Internacional